Lestaurtinib
Overview
Lestaurtinib (rINN, codenamed CEP-701) is a tyrosine kinase inhibitor undergoing research for the treatment of acute myelogenous leukemia (AML) and myeloproliferative disorders. It is an analog of staurosporine.
As of 2008, it is currently in Phase III clinical trials for AML and Phase II clinical trials for myeloproliferative disorders. [1]
It is being developed by Cephalon.
References
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH